The team at imusyn has many years of experience in developing DNA-based tools for genomic profiling of polymorphic systems, which are primarily based on sequence-specific priming as well as next generation sequencing. For traditional Sanger sequencing a gene-specific proprietary amplification strategy is used to determine the cis-phase of polymorphic sites.
With customized solutions and proprietary technologies, we perform contract development in partnership with our clients to ensure efficient and high quality product solutions. We at imusyn know that customer satisfaction is closely related to the quality of our work. Therefore, it is our focus to deliver the highest possible quality to all our partners. Staff expertise as well as formalised internal processes enables imusyn to deliver fast and flexible, state-of-the-art services for each and every customer.
To date imusyn has produced more than 30 products to advance allogeneic cellular therapies including PCR-based diagnostic tests for HLA typing. We are currently producing a number of CE-marked diagnostic assays, and have also been involved in numerous assay development projects throughout Europe and the US.